Trending: Roche to Buy Poseida Therapeutics for Up to $1.5 Billion

Dow Jones

2024-11-26

10:12 ET -- Roche is one of the most mentioned companies in the U.S. across all news items in the past 12 hours, according to Factiva data. Roche agreed to buy San Diego-based Poseida Therapeutics in a deal worth up to $1.5 billion, as the company seeks to expand its pipeline and support growth. The deal allows the Swiss pharmaceutical company to bring in house its current partner with the aim of developing cell therapies in oncology, immunology and neurology. Roche is buying Poseida Therapeutics for about $1 billion, or $9 a share, with additional performance-related payments worth up to $4 a share that could take the full deal value to around $1.5 billion. Poseida shares closed at $2.86 Monday. Dow Jones & Co. owns Factiva. (chris.wack@wsj.com)

(END) Dow Jones Newswires

November 26, 2024 10:12 ET (15:12 GMT)

Copyright (c) 2024 Dow Jones & Company, Inc.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2486002310"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2486002310\",edition:\"fundamental\",,,undefined,":{"share":"https://ttm.financial/m/news/2486002310?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-11-26 23:12","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2486002310","market":"hk","top_or_hot":-1,"title":"Trending: Roche to Buy Poseida Therapeutics for Up to $1.5 Billion","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n  10:12 ET -- Roche is one of the most mentioned companies in the U.S. across all news items in the past 12 hours, according to Factiva data. Roche agreed to buy San Diego-based Poseida <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> in a deal worth up to $1.5 billion, as the company seeks to expand its pipeline and support growth. The deal allows the Swiss pharmaceutical company to bring in house its current partner with the aim of developing cell therapies in oncology, immunology and neurology. Roche is buying Poseida Therapeutics for about $1 billion, or $9 a share, with additional performance-related payments worth up to $4 a share that could take the full deal value to around $1.5 billion. Poseida shares closed at $2.86 Monday. Dow Jones &amp; Co. owns Factiva. (chris.wack@wsj.com) \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  November 26, 2024 10:12 ET (15:12 GMT)\n</p>\n<p>\n  Copyright (c) 2024 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Trending: Roche to Buy Poseida Therapeutics for Up to $1.5 Billion</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nTrending: Roche to Buy Poseida Therapeutics for Up to $1.5 Billion\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2024-11-26 23:12</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n  10:12 ET -- Roche is one of the most mentioned companies in the U.S. across all news items in the past 12 hours, according to Factiva data. Roche agreed to buy San Diego-based Poseida <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> in a deal worth up to $1.5 billion, as the company seeks to expand its pipeline and support growth. The deal allows the Swiss pharmaceutical company to bring in house its current partner with the aim of developing cell therapies in oncology, immunology and neurology. Roche is buying Poseida Therapeutics for about $1 billion, or $9 a share, with additional performance-related payments worth up to $4 a share that could take the full deal value to around $1.5 billion. Poseida shares closed at $2.86 Monday. Dow Jones &amp; Co. owns Factiva. (chris.wack@wsj.com) \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  November 26, 2024 10:12 ET (15:12 GMT)\n</p>\n<p>\n  Copyright (c) 2024 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LENZ","symbol_name":"Therapeutics","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2486002310","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2486002310","pubTimestamp":1732633920,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"10:12 ET -- Roche is one of the most mentioned companies in the U.S. across all news items in the past 12 hours, according to Factiva data. Roche agreed to buy San Diego-based Poseida Therapeutics in a deal worth up to $1.5 billion, as the company seeks to expand its pipeline and support growth. The deal allows the Swiss pharmaceutical company to bring in house its current partner with the aim of developing cell therapies in oncology, immunology and neurology. Roche is buying Poseida Therapeutics for about $1 billion, or $9 a share, with additional performance-related payments worth up to $4 a share that could take the full deal value to around $1.5 billion. Poseida shares closed at $2.86 Monday. Dow Jones & Co. owns Factiva. ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"LENZ":"Therapeutics","BK4007":"制药","03165":"华夏欧优股对冲","RHHBY":"罗氏控股","PSTX":"Poseida Therapeutics, Inc.","BK4139":"生物科技"},"translate_title":"热门话题：罗氏将以高达15亿美元收购Poseida Therapeutics","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"03165":0.6,"LENZ":1,"PSTX":1,"RHHBY":0.9},"content_text":"10:12 ET -- Roche is one of the most mentioned companies in the U.S. across all news items in the past 12 hours, according to Factiva data. Roche agreed to buy San Diego-based Poseida Therapeutics in a deal worth up to $1.5 billion, as the company seeks to expand its pipeline and support growth. The deal allows the Swiss pharmaceutical company to bring in house its current partner with the aim of developing cell therapies in oncology, immunology and neurology. Roche is buying Poseida Therapeutics for about $1 billion, or $9 a share, with additional performance-related payments worth up to $4 a share that could take the full deal value to around $1.5 billion. Poseida shares closed at $2.86 Monday. Dow Jones & Co. owns Factiva. (chris.wack@wsj.com) \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  November 26, 2024 10:12 ET (15:12 GMT)\n\n\n  Copyright (c) 2024 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"symbols":[],"gpt_button":0,"code":"91000000","status":"200"}}}